{"slideshow_credits": null, "snippet": "GlaxoSmithKline of Britain is in talks to buy Human Genome Sciences on friendly terms, potentially ending a hostile bid for the maker of a promising treatment for lupus, a person briefed on the matter said Sunday.", "abstract": "GlaxoSmithKline of Britain is in talks to buy Human Genome Sciences on friendly terms, potentially ending a hostile bid for the maker of a promising treatment for lupus, a person briefed on the matter said Sunday.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"lastname": "DE LA MERCED", "rank": 1, "firstname": "Michael", "role": "reported", "organization": "", "middlename": "J."}], "original": "By MICHAEL J. DE LA MERCED"}, "web_url": "http://dealbook.nytimes.com/2012/07/15/glaxosmithkline-in-talks-to-buy-human-genome/", "lead_paragraph": null, "headline": {"main": "Glaxo to Buy Human Genome Sciences for $3 Billion", "print_headline": "Glaxo and Rival Drug Firm Are Said to Be Near a Deal", "kicker": "DealBook"}, "_id": "500340821c22dfde670b04ab", "word_count": "527", "multimedia": [], "pub_date": "2012-07-15T18:07:29Z", "source": "The New York Times", "news_desk": null, "keywords": [{"name": "organizations", "value": "GlaxoSmithKline PLC", "rank": "1"}, {"name": "organizations", "value": "Human Genome Sciences Inc", "rank": "2"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": "1"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "rank": "2"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}